<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q/A
(Mark One)
|X| QUARTERLY REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 1998 or
|_| TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from to .
--------- ----------
Commission File No. 0-15098
JONES PHARMA INCORPORATED
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 43-1229854
- ---------------------------------------- ------------------------------------
(State or other jurisdiction of (I.R.S. Employer Identification No.)
incorporation or organization)
1945 CRAIG ROAD, ST. LOUIS MISSOURI 63146
- ---------------------------------------- ------------------------------------
(Address of principal executive offices) (Zip Code)
(314) 576-6100
- --------------------------------------------------------------------------------
(Registrant's telephone number, including area code)
JONES MEDICAL INDUSTRIES, INC.
- --------------------------------------------------------------------------------
(Former Name, Former Address and Former Fiscal Year,
if Changed Since Last Report)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No ___
Number of shares outstanding of registrant's Common Stock as of August 2,
1998: 28,736,008.
<PAGE> 2
The following Form 10-Q/A is being submitted to amend the Form 10-Q for the
quarterly period ended June 30, 1998 which was filed by JONES PHARMA
INCORPORATED ("Registrant") on August 14, 1998. In its Form 10-Q filed on August
14, 1998, the Registrant unintentionally omitted information required to be
submitted in Items 4 and 6 of Part II.
This Form 10-Q/A summarizes the results of the shareholder vote in
connection with the Registrant's Annual Meeting with respect to: (i) the
election of the nominees to the Board of Directors; and (ii) the amendment to
the Registrant's Amended and Restated Certificate of Incorporation changing its
corporate name.
In addition, this Form 10-Q/A discloses two (2) reports on Form 8-K which
were filed by the Registrant during the quarterly period ended June 30, 1998,
including a report on Form 8-K announcing the filing of the amendment to its
Amended and Restated Certificate of Incorporation with the Secretary of State of
Delaware reflecting the name change.
PART II
OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
The Annual Meeting of Shareholders of Jones Medical Industries, Inc. was
held on May 19, 1998. The following proposals were adopted by the margins
indicated:
(1) Each of the nine nominees to the Board of Directors was elected for a
one-year term by the shareholders:
<TABLE>
<CAPTION>
DIRECTOR FOR WITHHELD
-------- --- --------
<S> <C> <C>
Dennis M. Jones 18,085,780 153,378
Judith A. Jones 18,085,530 153,628
Michael T. Bramblett 18,086,603 152,555
G. Andrew Franz 18,086,500 152,658
David A. McLaughlin 18,090,006 149,098
Stanley L. Lopata 18,086,336 152,822
L. John Polite, Jr. 18,089,881 149,277
Edward A. Chod 17,928,175 310,983
Thomas F. Patton, Ph.D. 18,093,975 145,183
</TABLE>
(2) The shareholders approved the proposed amendment to the Registrant's
Amended and Restated Certificate of Incorporation changing its
corporate name to JONES PHARMA INCORPORATED:
For 17,459,285
Against 648,382
Abstain 131,491
2
<PAGE> 3
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits:
NONE.
(b) Reports on Form 8-K:
The Registrant filed the following two (2) Current Reports on
Form 8-K during the quarter for which this Report on Form 10-Q
is filed:
1. Current Report on Form 8-K filed May 15, 1998 reporting,
pursuant to Item 2 of Form 8-K, the Registrant's completion
of the sale of certain of its assets to Twin Laboratories
Inc. and certain of its subsidiaries (collectively, "Twin")
as part of the Registrant's plan to discontinue and dispose
of its nutritional supplements product line and contract
manufacturing operations (the "Plan"). In addition, this Form
8-K pursuant to Item 7 of Form 8-K: (i) incorporated by
reference the pro-forma financial information relating to the
Plan which was filed as part of the Registrant's Form 10-K
for the fiscal year ended December 31, 1997 and its Form 10-Q
for the quarterly period ended March 31, 1998; and (ii)
included, as an exhibit, a copy of the definitive agreement
with Twin.
2. Current Report on Form 8-K filed May 20, 1998 announcing,
pursuant to Item 5 of Form 8-K, the filing of an amendment to
the Registrant's Restated Certificate of Incorporation
changing its corporate name.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
JONES PHARMA INCORPORATED
Date: January 29, 1999 By: /s/ Dennis M. Jones
---------------- -----------------------------------------
Dennis M. Jones, President
Date: January 29, 1999 By: /s/ Judith A. Jones
---------------- -----------------------------------------
Judith A. Jones, Executive Vice President
and Principal Financial and Accounting
Officer
3
